vaccine year end

The headquarters of German immunotherapy company BioNTech stands on April 22, 2020 in Mainz, Germany. BioNTech and U.S. pharmaceutical giant Pfizer are collaborating on a possible vaccine against Covid-19. (Thomas Lohnes/Getty Images)

NEW YORK — Pfizer, which has struck a nearly $2 billion deal with the United States government to deliver 100 million doses of a COVID-19 vaccine developed in collaboration with its German partner BioNTech, is hoping to seek regulatory approval for a vaccine "as early as October" this year and have a vaccine on the market by year end.

A "best case scenario" would be approval before year end and a vaccine by year end, according to Pfizer.

"In the third quarter of this year, we hope to get into the hospital setting with a drug that is given intravenously to patients hospitalized with COVID," John Burkhardt, senior vice president, Drug Safety Research and Development at Pfizer, said at a news conference in Connecticut July 22.

"An interesting thing about this vaccine approach is that the mRNA is enclosed in a lipid nanoparticle, so you can imagine the complexity of that. At this site, we are looking at engineering that particle and analyses for it that will allow clinical trials as well as the manufacturing to occur," Burkhardt said.

He promised Americans "safety will not be compromised" in vaccine development. "We are very optimistic,” he said.

Americans will receive the vaccine for free and the U.S. government can acquire up to an additional 500 million doses. Pfizer and BioNTech said in a statement they could potentially produce more than 1.3 billion doses by the end of 2021.

"Pfizer is one of the leading horses in this race right now. There may be several winners. We need several winners," Connecticut Governor Ned Lamont said at the news conference.

Pfizer's Groton, Connecticut facility has a long history of drug discovery and development including Zoloft and Zithromax.

Pfizer's vaccine candidate will now go into large scale clinical trials involving 20,000-30,000 patients before end July. It must be proven effective and receive emergency authorization before it can be distributed.

Pfizer is finishing an earlier stage of testing to determine which of four possible candidates to try in the final study.

Preliminary data from studies have shown a good immune response from vaccinated patients, Pfizer scientists told reporters.

Pfizer and BioNTech are evaluating at least four experimental vaccines, each of which represents a unique combination of messenger RNA (mRNA) format and target antigen.

Pfizer received fast track status for two of four vaccine candidates last week based on preliminary data from ongoing Phase 1/2 studies in the United States and Germany.

Explaining the nuts and bolts of the "fast track" label, Burkhardt said the new status allows straight line access to U.S. health authorities.

"You don't sit around and write a 100 page document, send it for review, wait 45 days for the outcome. You can be on the telephone in real time," Burkhardt said.

Pfizer said an oral treatment for COVID-19 patients is also on its longlist.

Meanwhile, Pfizer hopes to have antiviral medication ready for clinical trials in August or September.

Also next week, a vaccine created by the National Institutes of Health and Moderna Inc. is ready to begin final-stage testing in a study of 30,000 people.

President Donald Trump called the federal government's $1.95 billion deal with Pfizer and biotech firm BioNTech "a historic agreement" that will help the country distribute a coronavirus vaccine in record-breaking time.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.